Healthcare & Life Sciences

Phase 3 BMAC vs Corticosteroid for TMJ Pain

NIH registered a Phase 3 randomized clinical trial (NCT07536399) comparing Bone Marrow Aspirate Concentrate (BMAC) injection versus corticosteroid injection during TMJ arthroscopy for patients with temporomandibular joint pain unresponsive to conservative treatment. The trial will enroll participants randomized to receive either BMAC or corticosteroid injection, with 3 follow-up visits over 6 months and MRI imaging.

Phase 1 3D1015 Injection Trial for Metastatic Castration-Resistant Prostate Cancer

NIH registered a Phase 1 clinical trial (NCT07537010) investigating 3D1015 Injection (Lu 177-PSMA-3D1015) in adult males with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). The open-label study will evaluate safety, tolerability, and dosimetry of intravenous infusions with dynamically individualized treatment regimens. Secondary objectives include assessing preliminary anti-tumor efficacy and optimal dosing.

VR Learning Program for Sexual-and-gender-diversity Care

NIH registered Clinical Trial NCT07535216 on ClinicalTrials.gov to study the effectiveness of a virtual reality (VR) learning program designed to improve nursing students' care practices for sexual and gender-diversity patients. The clinical trial will evaluate both short-term and long-term effects on caring behaviors. The study is listed with conditions including sex difference, virtual care, and nursing care, with an expected completion date of April 17, 2026.

Phase 2 Naxitamab Neuroblastoma Trial, 10 Patients, Apr 17

NIH ClinicalTrials.gov registered Phase 2 trial NCT07537400 evaluating Naxitamab and GM-CSF chemoimmunotherapy combined with COG-type induction chemotherapy in 10 newly diagnosed high-risk neuroblastoma patients aged 12 months to 21 years. The trial aims to assess safety over approximately 2 years. This registration adds to the publicly available record of pediatric oncology clinical research.

Effect of Patient Education Program on Vitamin D Levels and Health Beliefs

NIH has registered a clinical trial (NCT07535671) evaluating whether a structured patient education program improves health beliefs and medication adherence in patients with Vitamin D deficiency. The 6-month trial will randomize 120 adult hypothyroid female patients with serum Vitamin D below 30 ng/dL to either face-to-face education with brochures and monthly phone follow-ups or standard care. The intervention's effectiveness will be measured using the Medication Possession Ratio and serum 25(OH)D levels.

HEARTS Implementation for Hypertension-Diabetes Multimorbidity, Guatemala, 1,440 Adults

NIH's ClinicalTrials.gov has registered a new clinical study (NCT07536919) evaluating the WHO-developed HEARTS implementation program for comorbid hypertension and Type 2 diabetes. The pragmatic cluster-randomized trial will enroll 1,440 adults across 36 public primary care clinics in Guatemala. Participants are randomized to HEARTS intervention or current standard care, with primary outcomes (blood pressure and hemoglobin A1c) assessed at 12 months.

Virtual Roundtable Promotes STI Prevention Treatment During Awareness Week

The New York State Department of Health hosted a virtual roundtable during STI Awareness Week (April 14-20, 2026) with experts from NYS, NYC, and community organizations to discuss STI prevention strategies, stigma reduction, and available resources. New 2024 data on chlamydia, gonorrhea, and syphilis was added to the state's STI Dashboard. Panelists emphasized the importance of screening, open conversations with providers, and equitable access to sexual health services.

Telerehabilitation in Patients With Elevated Pulmonary Artery Pressure

NIH registered clinical trial NCT07535398 on ClinicalTrials.gov studying whether synchronous telerehabilitation improves exercise capacity, dyspnea, fatigue, functional status, and quality of life in patients with elevated pulmonary artery pressure (systolic PAP ≥50 mmHg). The randomized controlled trial will compare an 8-week telerehabilitation program (3 sessions/week, 30 min/session) against breathing and posture exercises. Estimated completion date is April 17, 2026.

Phase 2 Auricular Point Stimulation Plus Dexamethasone for Chemotherapy-Induced Nausea and Vomiting (NCT07537699)

NIH ClinicalTrials.gov registered a Phase 2 clinical trial (NCT07537699) evaluating auricular point stimulation combined with dexamethasone for preventing chemotherapy-induced nausea and vomiting in breast cancer patients receiving docetaxel plus cyclophosphamide. The single-arm study will track nausea, vomiting, appetite, and gastrointestinal function from Day 1 through Day 5 of chemotherapy. Participating institutions and investigators must conduct the trial in accordance with the registered protocol, IRB oversight, and informed consent requirements.

SPSIP Block vs Rhomboid Block for Postoperative Analgesia in Breast Cancer Surgery: Randomized Controlled Trial

This ClinicalTrials.gov registry entry announces a randomized controlled trial (NCT07536867) comparing the analgesic efficacy of Serratus Posterior Superior Intercostal Plane (SPSIP) Block versus Rhomboid Intercostal Block for postoperative pain management following breast cancer surgery with axillary lymph node dissection. The primary outcome is Visual Analog Scale pain scores during the first 24 hours post-surgery. Secondary outcomes include opioid consumption, rescue analgesia requirements, block performance time, and patient satisfaction. The study is currently recruiting.

i-PRF Perfusion Trial for Moderate to Severe Intrauterine Adhesions

NIH's ClinicalTrials.gov registered a new prospective randomized controlled study (NCT07536971) evaluating the efficacy and safety of intrauterine i-PRF (injectable platelet-rich fibrin) perfusion in women with moderate to severe intrauterine adhesions after hysteroscopic adhesiolysis. The trial will compare i-PRF intrauterine perfusion against sodium hyaluronate intrauterine treatment, assessing endometrial regeneration and reproductive outcomes. The anticipated study start date is April 17, 2026.

Observational Study of Pre-Anaesthesia Person-Centred Care in Danish Hospitals

The NIH ClinicalTrials.gov registry has published registration details for observational study NCT07535450, an observational study examining pre-anaesthesia practices and patient experiences in Danish public hospitals. The study will collect patient survey data on what matters to patients before anaesthesia and the degree of person-centredness in pre-anaesthesia consultations.

AI LSTM Forecasting Depth of Anesthesia Trial

The National Institutes of Health registered observational clinical trial NCT07536230 on ClinicalTrials.gov, investigating the use of Long Short-Term Memory (LSTM) deep learning networks to forecast depth of anesthesia. The study aims to deploy AI frameworks to predict patient-specific physiological states by processing time-series BIS-EEG data, moving beyond traditional PK/PD models like the Eleveld model for Propofol and Remifentanil. This trial involves adult patients undergoing procedures requiring general anesthesia and will evaluate the predictive accuracy of AI-driven forecasting versus standard concentration estimation models.

Methadone Perception Survey Targets Pediatric Surgical Caregivers

An observational survey study (NCT07537608) examining methadone perceptions among caregivers of pediatric outpatient surgical patients, orthopedic surgeons, and anesthesiologists has been registered on ClinicalTrials.gov. The study will investigate associations between social determinants of health and attitudes toward methadone use for postoperative pain. Healthcare providers and clinical researchers should monitor this registry for emerging evidence on potential disparities in pain management perceptions.

OCU500 ChAd36 Vector COVID-19 Vaccine Phase 1 Trial, 80 Participants

A Phase 1 randomized, open-label, dose-escalation clinical trial registered for OCU500, a ChAd36 vector vaccine encoding SARS-CoV-2 spike protein, administered via intranasal and inhalational routes. The trial enrolls 80 healthy adults (aged 18-64) previously vaccinated with a primary COVID-19 series and at least one booster. Participants will receive one of two dose levels (1×10^10 VP or 5×10^10 VP) across four study arms of 20 participants each, with the primary objective of evaluating safety and reactogenicity.

Comparative Efficacy of Electromagnetic Field Therapy and Tibial Nerve Stimulation in Urge Urinary Incontinence

NIH registered Clinical Trial NCT07536139 on ClinicalTrials.gov, a prospective, randomized, assessor-blinded clinical trial comparing pulsed electromagnetic field (PEMF) therapy and posterior tibial nerve stimulation (PTNS) for treatment of urge urinary incontinence in women. Eligible participants will be randomized to one of two intervention groups and assessed at baseline and post-treatment using validated instruments including the ICIQ-SF, bladder diaries, and quality-of-life scales. The primary objective is to compare efficacy of the two modalities in reducing urinary symptoms. No compliance obligations or deadlines are imposed by this registration record.

NCT07536243: Emotion Regulation RCT for Eco Anxiety and Eating Concerns in Mexican Adults

The National Institutes of Health registered clinical trial NCT07536243, a randomized controlled trial evaluating a group-based emotion regulation intervention for eco-anxiety and eating-related eco-concerns in Mexican adults aged 18 and older. The six-week intervention will be assessed at baseline, post-intervention, and four-month follow-up, comparing the treatment group to a control group. Participants will attend weekly sessions and complete assessment instruments at three time points.

CIRCLE-Asia Phase 3 Trial: Colchicine for Chronic Limb-Threatening Ischemia

The CIRCLE-Asia trial (NCT07536373) is a Phase 3 randomized, double-blind, placebo-controlled multicenter study evaluating colchicine 0.5mg daily versus placebo in 200 adult patients with chronic limb-threatening ischemia who have undergone successful revascularization. The trial will be conducted at five hospitals in Taiwan with treatment beginning within 7 days of the procedure. Participants will be monitored for reduction of complications and limb events.

HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS, AND METHODS OF USE THEREOF

The European Patent Office published patent application EP2023216237A1 for JS Innomed Holdings Ltd., covering heterocyclic compounds as kinase inhibitors, compositions, and methods of use. The A1 publication indicates the application has passed formal examination and is now open for opposition. The patent covers compounds classified under IPC C07D 471/04 with therapeutic applications in A61K 31/437 and A61P 35/00 (oncology). The designated states include all current EU member states plus associated countries.

PIKFYVE Inhibitor Compounds Patent Application - C07D 487/04

European Patent Office published patent application EP4444316A1 for PIKFYVE inhibitor compounds and pharmaceutical compositions. The application, filed by Kineta, Inc., covers heterocyclic compounds (C07D 487/04) with therapeutic applications including neurological conditions (A61P 25/28). Inventors include Kumaravel, Macdonnell, and Peng. A1 publication indicates the application has entered the European phase and is publicly available for examination.

Fused Benzoisoxazolyl Compounds as KAT6A Inhibitors

The European Patent Office published patent application EP4448109A1 for fused benzoisoxazolyl compounds as KAT6A inhibitors, filed jointly by Aurigene Oncology Limited and Olema Pharmaceuticals, Inc. The invention covers heterocyclic antineoplastic compounds classified under A61P 35/00 and C07D 498/04. The patent is designated for all European Patent Convention contracting states.

Phenoxy and Benzyloxy Substituted Psychoplastogens and Uses Thereof

The European Patent Office published patent application EP4448531A1 for Delix Therapeutics covering phenoxy and benzyloxy substituted psychoplastogens and their therapeutic uses. The patent application lists designations across 31 European states and territories. The compounds are classified under IPC C07D 487/04 with therapeutic applications including neurological and psychiatric conditions such as anxiety, Alzheimer's disease, and addiction disorders.

Pyrimidine Tricyclic Derivative and Pharmaceutical Application (EP4417613A1)

EPO granted patent EP4417613A1 to CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. The patent covers pyrimidine tricyclic derivatives and their pharmaceutical applications. The patent is designated in multiple contracting states including DE, FR, GB, IT, ES, NL, SE, PL, and other EU member states.

Hinova's Heterocyclic AR Degrader EP4378936A1

The European Patent Office published patent application EP4378936A1, filed by Hinova Pharmaceuticals Inc., covering bifunctional chimeric heterocyclic compounds designed to degrade androgen receptors for therapeutic use. The patent designates 31 EPO member states and classifies under C07D (heterocyclic compounds), A61K (pharmaceutical preparations), and A61P 35/00 (anticancer agents). The filing names 17 inventors and represents a pharmaceutical manufacturer's IP protection strategy for a targeted cancer therapy compound.

Novel PARP7 Inhibitor and Use Thereof

The European Patent Office published patent application EP4378938A1 filed by Shanghai Qilu Pharmaceutical Research and Development Centre Ltd., covering a novel PARP7 inhibitor and its therapeutic use. The application was published on April 8, 2026 under IPC classification C07D 403/10 (A61P 35/00 for anticancer indications). The designated states cover all major European Patent Convention contracting states including DE, FR, GB, IT, ES, NL, BE, CH, and others.

PSMA Targeting Ligand Compound for Prostate Cancer Diagnosis and Treatment

The European Patent Office published patent application EP4431503A1 filed by Chengdu StarRay Therapeutics Co., Ltd. covering ligand compounds that target PSMA (Prostate-Specific Membrane Antigen) for use in prostate cancer diagnosis and treatment. The application includes claims for chelate compounds and their therapeutic and diagnostic applications. The patent is classified under IPC codes C07D 401/12, C07F 5/00, A61K 51/04, and A61P 35/00, covering 37 designated contracting states.

EP4426712A1 - Processable Compositions Patent

The European Patent Office published patent application EP4426712A1 filed by Ripple Therapeutics Corporation on April 8, 2026. The patent covers processable compositions including steroidal compounds and heterocyclic derivatives with potential therapeutic applications spanning cardiovascular treatments, glaucoma, and ocular hypertension. The designated contracting states cover all major European Economic Area nations including Germany, France, the United Kingdom, Italy, Spain, and the Netherlands.

Organic Molecules for Optoelectronic Devices - Samsung Display EP4472973A1

The European Patent Office granted Samsung Display Co., Ltd. Patent EP4472973A1 for organic molecules used in optoelectronic devices. The patent covers compounds classified under C07D 405/14 and H10K with applications in display technology. The designation covers 31 European contracting states including major markets such as DE, FR, GB, IT, and ES.

Long Acting GLP-1 Receptor Agonists and Methods of Use

The European Patent Office published patent application EP4263587A1 for long-acting GLP-1 receptor agonists filed by I2O Therapeutics, Inc. The patent covers glucagon-like polypeptide-1 receptor agonist compositions and methods of use for treating metabolic disorders including obesity, hyperlipidemia, and diabetes. The patent is directed to peptide compounds classified under C07K 14/605 with designated protection across 31 European member states.

IL10 Receptor Binding Molecules and Methods of Use - EP4192880A2

The European Patent Office published application EP4192880A2, a patent for IL10 receptor binding molecules and methods of use, filed by Synthekine, Inc. The patent covers C07K peptide-based compounds under classifications C07K 16/28, C07K 14/715, and C07K 14/705. The application designates all EU member states and participating EPC contracting states including CH, LI, NO, TR, and MC.

Modified B Cells and Methods of Use Thereof - EP4203978A1

The European Patent Office published patent application EP4203978A1 for Modified B Cells and Methods of Use Thereof, filed by Walking Fish Therapeutics, Inc. The patent covers engineered B cells for therapeutic applications, including cancer treatment indications (A61P 35/00). The application contains 18 IPC classifications spanning peptides, immunology, gene therapy vectors, and therapeutic preparations.

Tetravalent Bispecific Antibody, Preparation Method Therefor, and Use Thereof

The European Patent Office published patent application EP3967711A1 for a tetravalent bispecific antibody filed by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. The application covers the antibody's preparation method and therapeutic uses. The A1 publication includes a European search report and designates 32 member states including AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, and TR.

ENPP1 Antibody Inhibitors - University of California

The European Patent Office published application EP4146706A1 for ENPP1 antibody inhibitors filed by The Regents of the University of California. The application claims anti-ENPP1 antibodies for therapeutic use, classified under IPC C07K 16/40, A61P 9/10, A61K 39/395, and C12N 15/63. The application designates all relevant European member states including AT, BE, DE, FR, GB, IT, NL, ES, PL, and 25 others.

Orthogonal Mutations for Heterodimerization - Invenra Inc.

EPO published patent application EP4259194A1 titled 'Orthogonal Mutations for Heterodimerization' filed by Invenra Inc. The invention relates to methods for creating orthogonal mutation pairs to facilitate controlled heterodimerization of proteins, with applications in bispecific antibody development and therapeutic protein engineering. The application covers 47 designated EU member and extension states including Germany, France, UK, Italy, Spain, and other EPC contracting states.

Fate Therapeutics iPSC Effector Cells for Immunotherapy Patent EP4168538A1

The European Patent Office published patent application EP4168538A1 for Fate Therapeutics, Inc., covering methods of combining iPSC-derived effector cell types for immunotherapy use. The patent includes claims related to cell therapy compositions, cytokine combinations, and therapeutic applications for cancer treatment. The patent designation covers 31 European member states.

EP4146277A1 - Avian Antibodies Reduce Viral Disease Transmission

The European Patent Office granted Patent EP4146277A1 to Camas Incorporated on April 8, 2026, covering compositions and methods for using avian antibodies to reduce viral disease transmission. The patent names nine inventors and is classified under IPC categories A61K 39/42, A61P 11/00, A61P 31/12, and C07K 16/08. The patent is designated across 31 European states including Germany, France, the United Kingdom, Italy, and Spain.

EP4200339A2 - Compositions and Methods Related to Receptor Pairings

European Patent Office granted Patent EP4200339A2 to Synthekine, Inc. covering compositions and methods related to receptor pairings. The patent application, filed with IPC classifications C07K 16/28, C07K 14/715, and C07K 14/705, lists inventors KASTELEIN Robert, LUPARDUS Patrick J., and ROKKAM Deepti. The patent is designated across all European member states.

Measles Cases Rise to 602 in Utah

The Utah Department of Health and Human Services (DHHS) has reported 602 confirmed measles cases in Utah as of April 14, 2026, since the outbreak began in June 2025. The update reminds Utahns that the MMR vaccine is 97% effective after two doses and advises those exposed to monitor their health for 21 days. Healthcare providers are urged to prepare before symptomatic patients arrive to prevent further transmission.

ctDNA-driven Anti-EGFR Retreatment Metastatic Colorectal Cancer Study

NIH's ClinicalTrials.gov registered NCT07536113, an observational, retrospective, international multicenter study evaluating anti-EGFR rechallenge regimens in the largest real-world cohort of MSS mCRC patients. The study, funded by Fondazione Oncologia Niguarda ETS, will screen patients for RAS/BRAF/PIK3CA ctDNA status via liquid biopsy within the MEN1611-02 C-PRECISE-01 trial and collect molecular, clinical, and outcome data already available at participating centers.

Integrating Supports to Promote PrEP for Black Adolescents Working With Apps - Atlanta

NIH has registered a clinical trial (NCT07535346) evaluating the Health MPowerment app as a behavioral intervention to promote PrEP adherence among Black adolescents and young adults in Atlanta. The study applies Social Cognitive Theory to assess feasibility and acceptability of the enhanced HMP app as a support tool. The trial targets Black AYAs and adult supports as participants, with data collection anticipated through April 2026.

Effect of Tai Chi and Multimodal Exercise in Overweight and Obese Women

NIH registered clinical trial NCT07536893 examines the effects of a 10-week Tai Chi and Multimodal exercise program on balance in overweight and obese women. The study found that both Tai Chi and multimodal exercise programs significantly improved balance parameters compared to baseline. The research addresses a gap in the literature regarding balance-focused interventions as a primary goal for improving physical mobility in overweight individuals.

Evaluation of Serum Autophagic Biomarkers in Acute Response to Walking and Cycling in Healthy Males

NIH ClinicalTrials.gov registered observational study NCT07536659 evaluating serum autophagic biomarkers in healthy male individuals responding to walking and cycling exercises. The study aims to assess acute cellular responses to different physical exercise modalities through peripheral blood analysis, building on limited existing human data in this area.

First-in-man Trial TRICENTO G2 Transcatheter Valve for Tricuspid Regurgitation

The NIH ClinicalTrials.gov registry has posted a first-in-man trial for the TRICENTO G2 Transcatheter Valve System (TRICENTO G2 TVSTR) intended to treat severe tricuspid regurgitation in adult patients. The early feasibility study will assess safety, performance, and clinical benefit through 1-year follow-up. Participants will undergo minimally invasive valve implantation with clinic visits at baseline, 30 days, 3 months, 6 months, and 1 year post-procedure.

Montelukast Phase 2 Trial for Acute Myocardial Infarction

NIH registered a Phase 2 randomized controlled trial (NCT07537868) evaluating Montelukast 10 mg oral tablets for acute myocardial infarction. The trial, sponsored by Mansoura University (Egypt), will enroll participants randomized to Montelukast or placebo to assess anti-inflammatory and cardioprotective effects via inflammatory markers and cardiac injury indicators. The study has an estimated start date of April 17, 2026.

IBM Dietary Surveillance Study at Manchester Metropolitan University

The NIH ClinicalTrials.gov registry has added a new observational study (NCT07535996) titled 'IBM Dietary Surveillance Study' at Manchester Metropolitan University. The study will investigate how diet affects muscle health and functional ability in adults with inclusion body myositis (IBM) compared to healthy volunteers aged 40 and older. Participants will complete dietary records, physical activity monitoring, body composition assessments, and muscle function tests over a four-week home monitoring period plus two university visits.

IPG11406 Phase 2 UC Trial, 144 Patients, 12 Weeks

NIH has registered a Phase 2 clinical trial (NCT07535489) for IPG11406, an investigational oral drug targeting the GPR183 receptor for ulcerative colitis. The randomized, double-blind, placebo-controlled study will enroll 144 adult patients across three active dose groups (10 mg, 20 mg, 40 mg twice daily) and one placebo arm over 12 weeks. The primary endpoint is clinical remission measured by modified Mayo Score at week 12, with secondary endpoints including clinical response, endoscopic remission, histological improvement, and safety evaluation.

First-in-human SRP-1005 Huntington's Disease Phase 1 Trial

NIH ClinicalTrials.gov registered a first-in-human Phase 1 trial (NCT07536061) studying SRP-1005, an investigational treatment for Huntington's Disease. The multi-center trial will evaluate the safety and tolerability of SRP-1005 versus placebo in participants with Huntington's Disease. The trial has an anticipated start date of April 17, 2026.

Mirror Therapy for Complex Regional Pain Syndrome in Post-Stroke Patients

The NIH ClinicalTrials.gov registry has registered a clinical trial (NCT07537465) evaluating mirror therapy for complex regional pain syndrome in post-stroke patients. The randomized controlled trial will compare mirror therapy to sham mirror therapy over 4 weeks. Participants will receive conventional rehabilitation therapy and be assessed using clinical scales, electrophysiological tests, and ultrasonographic measurements.

Observational Study, Adolescent Rights, Rural Assiut, Egypt

NIH registered observational study NCT07536555 on ClinicalTrials.gov, titled 'Adolescent Rights Fulfilment in Rural Assiut, Egypt'. The community-based cross-sectional study will assess fulfilment of adolescent rights in health, education, protection, and community participation among 300 adolescents aged 15-19 years in Beni Adi village, Assiut Governorate. Data collection is anticipated to begin April 17, 2026.

EUS-RFA for Pancreatic Cystic Neoplasms and Pancreatic Neuroendocrine Tumors

NIH ClinicalTrials.gov has registered a clinical trial (NCT07536087) evaluating endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) as a treatment for pancreatic cystic neoplasms and pancreatic neuroendocrine tumors in patients ineligible for or refusing surgery. The primary endpoints assess technical feasibility and effectiveness, while secondary objectives evaluate safety and long-term efficacy including adverse events and disease progression over one year of follow-up.